Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration
Authors Wingard JB, Delzell DAP, Houlihan NV, Lin J, Gieser JP
Received 23 October 2019
Accepted for publication 28 November 2019
Published 24 December 2019 Volume 2019:13 Pages 2563—2572
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Jeremy B Wingard,1 Darcie AP Delzell,2 Nathan V Houlihan,2 Jonathan Lin,2 Jon P Gieser1
1Wheaton Eye Clinic, Wheaton, IL 60187, USA; 2Mathematics and Computer Science Department, Wheaton College, Wheaton, IL, 60187, USA
Correspondence: Jeremy B Wingard
Wheaton Eye Clinic, 2015 N. Main Street, Wheaton, IL 60187, USA
Tel +1 630-668-8250
Purpose: To estimate the risk of glaucoma or sustained ocular hypertension (OHT) related to anti-vascular endothelial growth factor (VEGF) injections for age-related macular degeneration (AMD).
Design: Retrospective chart review.
Subjects: Patients who received unilateral anti-VEGF injections for AMD at the Wheaton Eye Clinic (IL).
Methods: Chart analysis was performed on 1095 patients, without prior glaucoma or OHT, who received unilateral anti-VEGF injections for AMD from 2005 to 2012, with data collected through 2013. Data collection included demographics, lens status, date and medication type of each injection, and the date of diagnosis of glaucoma or OHT by a treating glaucoma specialist, which was the main outcome measure. Rare events logistic regression was performed to determine the risk of disease development based on sex, lens status, and injection frequency.
Results: Unilateral glaucoma or sustained OHT developed in 42 patients over the course of follow-up, with 40 events in the injected eye only, 2 in the contralateral eye only. Statistical modeling predicted elevated risk for onset of glaucomatous disease with a higher maximum frequency of injections (p < 0.0001, odds ratio [OR] 2.18 for each additional injection over the most injection-intense 6 months for a given subject) and with phakic lens status (p = 0.0009, OR 0.33 for pseudophakia).
Conclusion: Our results show a significant risk for glaucoma or OHT development in patients undergoing repeated treatments with intravitreal anti-VEGF injections for AMD, establishing the first reliable connection between disease development and a period of high-frequency injections. In addition, we show a significantly increased risk of disease development in phakic patients, which we believe points to a mechanical explanation for this type of secondary glaucoma.
Keywords: exudative macular degeneration, secondary glaucoma, open-angle glaucoma, anti-vascular endothelial growth factor
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]